Clomipramine (Anafranil) and behaviour therapy in obsessive-compulsive and phobic disorders.
In a comparative study of three treatment regimens in patients with obsessive-compulsive or phobic manifestations, the most favourable therapeutic findings were seen in the clomipramine (Anafranil, Geigy Pharmaceuticals) plus behaviour therapy group and the least favourable therapeutic findings in the clomipramine plus simulated behaviour therapy group. The findings that a combination of behaviour therapy and clomipramine results in more favourable therapeutic changes than either of the two treatments alone is in line with reported studies in the literature.
D000328:Adult; D001521:Behavior Therapy; D002986:Clinical Trials as Topic; D002997:Clomipramine / Q000009:adverse effects / Q000627:therapeutic use*; D003984:Dibenzazepines / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000628:therapy; D010698:Phobic Disorders / Q000188:drug therapy* / Q000628:therapy
D003984:Dibenzazepines; D002997:Clomipramine